Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-7194

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-7194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended Release Tablets 50mg

Desvenlafaxine Extended-Release Tablets 50 mg extended release oral tablets, generic for Pristiq, manufactured by Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. The film-coated pink tablet packaging indicates strength as 50 mg desvenlafaxine per tablet. The label includes dosing instructions in English and Spanish and storage conditions.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A chart showing geometric mean ratios (90% confidence intervals) of Cmax and AUC pharmacokinetic parameters for Desvenlafaxine extended-release tablets, 50 mg, across varying degrees of renal and hepatic impairment, and different populations based on gender and age. The x-axis represents change relative to reference values, ranging from 0.5 to 3.5.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A pharmacokinetic chart showing the geometric mean ratio (90% confidence interval) of Cmax and AUC for Desvenlafaxine when administered with the CYP3A4 inhibitor ketoconazole. The horizontal axis represents change relative to reference, ranging from 0.5 to 2.0.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A forest plot showing geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC) of various drugs interacting with desvenlafaxine at different doses. The plot compares changes relative to reference values for drugs including desipramine, midazolam, tamoxifen, and aripiprazole, illustrating effects on their active metabolites as noted by asterisks.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A Kaplan-Meier survival curve chart showing the estimated proportion (%) of patients with relapse over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets 50 mg and placebo. The chart shows relapse rates increasing over nearly 200 days, with a lower relapse proportion in the Desvenlafaxine group than the placebo group.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A line chart depicting the estimated proportion of patients with relapse (%) over time in days from randomization, comparing Desvenlafaxine Extended-Release Tablets to placebo. The x-axis represents time to relapse in days, and the y-axis represents the estimated proportion of patients relapsing, showing distinct relapse rates for the two groups.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure of Desvenlafaxine Succinate with hydrate, showing its molecular components including aromatic rings, hydroxyl groups, amine, carboxylic acids, and hydrate water molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.